World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   46 records for 15 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2
Recruitment statusMain ID Public TitleDate of Registration
Not recruitingNCT01745367
Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer 06/12/2012
Not recruitingNCT01706861
A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid Lesions Treated Adjunctive to Surgical Excision
03/10/2012
Not recruitingNCT01446770
Evaluation of the Initial Safety and Efficacy of Keloid Lesions Treated With MF-4181
02/10/2011
AuthorisedEUCTR2009-017905-13-AT
A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] .
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2009-017905-13-ESEnsayo de Fase III, multicéntrico, de 3 brazos, aleatorizado, para evaluar la eficacia y seguridad de T-DM1 en combinación con pertuzumab ó T-DM1 en combinación con placebo de pertuzumab (ciego para pertuzumab), frente a la combinación de trastuzumab más taxano, como tratamiento de primera línea en pacientes con cáncer de mama en progresión, o avanzado localmente recurrente o metastásico, HER2-positivo. A randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2- positive progressive or recurrent locally advanced or metastatic breast cancer (MBC).23/03/2010
AuthorisedEUCTR2009-017905-13-FRA randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2- positive progressive or recurrent locally advanced or metastatic breast cancer (MBC).11/05/2010
AuthorisedEUCTR2009-017905-13-ITA randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2- positive progressive or recurrent locally advanced or metastatic breast cancer (MBC). - ND16/07/2010
AuthorisedEUCTR2009-017905-13-GRA randomized, 3 arm, multicentre, phase III study to evaluate the efficacy and the safety of T-DM1 combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for pertuzumab), versus the combination of trastuzumab plus taxane, as first line treatment in HER2- positive progressive or recurrent locally advanced or metastatic breast cancer (MBC).18/01/2011
AuthorisedEUCTR2009-017905-13-PTA Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] . 29/09/2010
AuthorisedEUCTR2009-017905-13-HUA Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] . 15/06/2010
AuthorisedEUCTR2009-017905-13-GBA Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] . 25/06/2010
AuthorisedEUCTR2009-017905-13-DEA Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] . 06/04/2010
AuthorisedEUCTR2009-017905-13-DKA Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] . 15/06/2010
AuthorisedEUCTR2009-017905-13-SEA Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] . 24/05/2010
AuthorisedEUCTR2009-017905-13-CZA Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] . 25/06/2010
Not RecruitingJPRN-JapicCTI-111487Phase III clinical trial of RG3502 and RG1273 for breast cancer patients01/10/2012
AuthorisedEUCTR2009-017905-13-BEA Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer [MARIANNE] . 31/08/2010
Not recruitingNCT01120184A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)28/04/2010
23/03/2010
Not recruitingNCT00915018
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2008-007803-10-ESA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer Estudio de fase 3, aleatorizado, abierto y de dos grupos, de neratinib más paclitaxel versus trastuzumab más paclitaxel como tratamiento de primera línea en el cáncer de mama localmente recurrente o metastático positivo para ErbB-229/07/2009
Not RecruitingEUCTR2008-007803-10-PTA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer10/08/2009
AuthorisedEUCTR2008-007803-10-FRA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer04/09/2009
AuthorisedEUCTR2008-007803-10-GRA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer07/10/2009
Not RecruitingEUCTR2008-007803-10-DKA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer06/11/2009
AuthorisedEUCTR2008-007803-10-MTA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer01/12/2009
Not RecruitingEUCTR2008-007803-10-BGA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer18/02/2010
AuthorisedEUCTR2008-007803-10-LVClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer03/08/2009
AuthorisedEUCTR2008-007803-10-HUClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer18/06/2009
AuthorisedEUCTR2008-007803-10-GBClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer20/07/2009
Not RecruitingEUCTR2008-007803-10-ITA Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer - ND30/06/2009
Not RecruitingEUCTR2008-007803-10-DEClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer30/06/2009
AuthorisedEUCTR2008-007803-10-BEClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer31/07/2009
Not RecruitingEUCTR2008-007803-10-LTClinical research study comparing anti-tumor acitivty of an investigational drug (neratinib) plus paclitaxel and a combination therapy of trastuzumab (Herceptin) plus paclitaxel in patients with erbB-2 positive locally recurrent or metastatic breast cancer13/08/2009
Not RecruitingCTRI/2009/091/000942A Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer18-11-2009
04/06/2009
Not recruitingNCT00878709
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2008-007345-31-ITA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer - ND30/06/2009
Not RecruitingEUCTR2008-007345-31-ESA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer. Ensayo aleatorizado, en doble ciego y controlado con placebo, de neratinib (HKI-272) después de trastuzumab en mujeres con cáncer de mama en estadío inicial con sobreexpresión/amplificación de HER-2/neu29/07/2009
AuthorisedEUCTR2008-007345-31-FRA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.07/09/2009
AuthorisedEUCTR2008-007345-31-GRA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.08/10/2009
AuthorisedEUCTR2008-007345-31-MTA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.29/12/2009
AuthorisedEUCTR2008-007345-31-PTA Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer.30/08/2010
AuthorisedEUCTR2008-007345-31-GBNeratinib adjuvant study31/07/2009
AuthorisedEUCTR2008-007345-31-BGNeratinib adjuvant study18/02/2010
AuthorisedEUCTR2008-007345-31-CZNeratinib adjuvant study14/07/2009
AuthorisedEUCTR2008-007345-31-SENeratinib adjuvant study07/10/2009
AuthorisedEUCTR2008-007345-31-HUNeratinib adjuvant study18/06/2009
AuthorisedEUCTR2008-007345-31-LTNeratinib adjuvant study11/08/2009
AuthorisedEUCTR2008-007345-31-BENeratinib adjuvant study31/07/2009
AuthorisedEUCTR2008-007345-31-DKNeratinib adjuvant study16/09/2009
Not RecruitingEUCTR2008-007345-31-NLNeratinib adjuvant study01/09/2009
AuthorisedEUCTR2008-007345-31-DENeratinib adjuvant study23/06/2009
08/04/2009
Not recruitingNCT00824408
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
15/01/2009
Not recruitingNCT00517192
Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI
15/08/2007
Not recruitingNCT00341302
A Prospective, Observational Study of HIV-Infected Pregnant Women and Their Infants at Clinical Sites in Latin American and Caribbean Countries
19/06/2006
Not recruitingNCT00338247
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
16/06/2006
    
1 2
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history